Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome (NASDAQ:HIND) versus Medline (NASDAQ:MDLN) Critical Review
Vyome (NASDAQ:HIND) & Medline (NASDAQ:MDLN) Critical Analysis
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Analyzing Profusa (NASDAQ:PFSA) & Vyome (NASDAQ:HIND)
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Profusa (NASDAQ:PFSA) versus Vyome (NASDAQ:HIND) Head to Head Analysis
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings Announces Results of Annual Shareholder Meeting
Vyome Holdings Acquires MIT AI Spinout Oculo Health
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
Vyome Announces New Board of Directors with Deep MIT and AI Ties
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS